+ population and became unable to respond to multiple forms of immunotherapy and immunogenic chemotherapy. Conversely, increasing p53 expression using a p53-agonist drug caused a sustained increase in Ly6c + CD103
+ cells in tumors during immunotherapy, which markedly enhanced the efficacy and duration of response. Thus, p53-driven differentiation of Ly6c + CD103
+ monocytic cells represents a potent and previously unrecognized target for immunotherapy.
INTRODUCTION
The ability to elicit immunogenic antigen presentation in tumors is a key determinant of effective cancer immunotherapy (Chen and Mellman, 2013) . In order to create a self-amplifying, self-sustaining immune response, it is critical that antigens from the tumor be cross-presented to activate the patient's own T cells. Unfortunately, in most tumors, the available antigen-presenting cells (APCs) are profoundly dysfunctional (Ugel et al., 2015) .
In mouse tumor models, immunogenic cross-presentation requires a population of DCs dependent on the transcription factor Batf3 (Hildner et al., 2008) . In tissues, these DCs may express the cell-surface integrin CD103, as well as characteristic markers such as the transcription factor IRF8, the chemokine receptor XCR1, and CD24 (Durai and Murphy, 2016) . While these conventional CD103 + DCs can be present in tumors, they are often limited in number, and many tumors appear to actively exclude them (Spranger et al., 2015) . When present, however, CD103 + DCs cross-present tumor antigen (Roberts et al., 2016; Salmon et al., 2016) , provide pro-inflammatory interleukin-12 (IL-12) (Broz et al., 2014) , and are crucial for anti-tumor responses (Pfirschke et al., 2016; Salmon et al., 2016; Spranger et al., 2017) . The precise human counterpart of these cells is not yet established, but immunogenic DCs are likely to be equally important in human tumors as well (Broz et al., 2014; Spranger et al., 2017) .
However, in most tumors, immune suppression usually dominates over immune activation. It is not well understood how immunotherapy can be made to tip this balance, such that the tumor milieu now becomes immunogenic and pro-inflammatory. In the current study, we show that successful transformation to an immunogenic microenvironment critically depends on the differentiation of a population of monocytic-lineage cells, which are dependent on Batf3 and express CD103 but which derive directly from immature monocytic precursors, rather than from the DC lineage. In order to study tumors with a spontaneously immunogenic microenvironment, we used host mice with a targeted deletion of PTEN phosphatase in regulatory T (Treg) cells (Pten -/-Foxp3-cre mice). We have previously shown that the tumor-associated Treg cells in these mice spontaneously lose suppressive activity during inflammation (Sharma et al., 2015) . Tumors implanted in Pten -/-Foxp3-cre mice were chronically inflamed and could barely grow ( Figure 1A ). Analysis of these tumors showed a population of CD11c + cells bearing an unusual hybrid phenotype ( Figure 1A , dot plots and scatter plot). These cells expressed Ly6c, suggestive of myelomonocytic cells (Ugel et al., 2015) , but also expressed CD103, which is usually associated with Batf3-lineage ''conventional'' DCs (cDCs).
Ly6c + CD103 + Cells Emerge after Immunogenic
Chemotherapy Based on this, we asked whether similar Ly6c + CD103 + cells could be elicited in WT hosts, if the PTEN + Treg cells were blocked. We have previously shown that inhibiting PTEN enzymatic activity by treating mice with the vanadate drug VO-OHpic (Mak et al., 2010) renders PTEN + Treg cells in tumors highly unstable when exposed to inflammation or chemotherapy (Sharma et al., 2015) . (Details and caveats of this model are given in the STAR Methods.) Treatment of established tumors with VO-OHpic plus cyclophosphamide (CTX) chemotherapy triggered rapid tumor regression ( Figure 1B ). Neither CTX nor VO-OHpic by themselves had any effect, and we have shown that the synergy created by the combination is entirely immune mediated (Sharma et al., 2015) . As they regressed, treated tumors now contained large numbers of Ly6c + CD103 + cells, comprising up to 60% of the total CD11c + population ( Figure 1C ).
These Ly6c + CD103 + cells expressed myelomonocytic markers (Ly6c, CD11b, and Gr-1 int ) but also expressed CD103 and markers such as Batf3, IRF8, CD24, XCR1, and Flt3, shared by conventional Batf3-lineage DCs. None of the Ly6c + CD103
+ cells expressed the macrophage-associated marker F4/80, but all expressed CD86 and IL-12, suggesting a pro-inflammatory phenotype.
The Ly6c + CD103 + population emerged rapidly, within 24 hr of chemotherapy (Figure S1A DCs or myeloid-derived suppressor cells (MDSCs) from the same tumor, were able to re-activate the anergic T cells (Figure 1D ). Reversal of anergy was dependent on production of IL-12, as shown by neutralizing antibody ( Figure 1D , red arrow).
(In these studies, the MDSCs and other DCs doubtless had various suppressive mechanisms that interfered with their effectiveness as APCs; we did not attempt to block these, because the key point was that the Ly6c + CD103 + cells were spontaneously stimulatory, directly ex vivo and without any manipulation.)
Ly6c
+ CD103 + Cells Can Differentiate from Ly6c + Immature Myeloid Cells in a Batf3-Dependent Fashion The Ly6c + CD103 + population emerged so rapidly following treatment (in <24 hr) that it suggested they might be arising from cells already present in the tumor or circulation. The expression of Ly6c, CD11b, and Gr-1 markers was reminiscent of the monocytic MDSCs elicited by tumors (Ugel et al., 2015) . Considered in bulk, MDSCs are immunosuppressive. However, some MDSCs resemble immature versions of the inflammatory DCs seen in infection (Goldszmid et al., 2014) and MDSCs may be able to further differentiate under certain conditions (Ma et al., 2013; Marigo et al., 2016 (Figure 2A ). In vivo, the Ly6c + CD103 + population expressed multiple markers reminiscent of conventional CD103 + cDCs (cf. Figure 1B) , and in cDCs this phenotype would normally be controlled by the transcription factor Batf3 (Durai and Murphy, 2016) . We hypothesized that Batf3 might become ectopically activated in Ly6c + myeloid precursor cells in response to inflammation. Figure 2A shows that the immature Ly6c + CD11c -cells upregulated Batf3 during differentiation in vitro. Silencing of Batf3 with siRNA abrogated acquisition of CD103 and associated markers (red boxes). Consistent with this, Batf3-deficient mice (Hildner et al., 2008) [Durai and Murphy, 2016] ), and none of them acquired Ly6c ( Figure 2B , scatter plots). Thus, the specific dual-positive Ly6c + CD103 + population appeared to arise from monocytic rather than dendritic-lineage precursors.
Monocytic Progenitor Cells Rescue Anti-tumor Activity in Batf3-Deficient Mice Batf3-deficient mice lack critical antigen-presenting activity required for anti-tumor immunity (Hildner et al., 2008) . Since Ly6c
+ cells upregulated Batf3 expression as they differentiated, we asked whether they could rescue functional immune responses in Batf3 -/-mice. Batf3 -/-mice showed essentially no anti-tumor effect of CTX+VO-OHpic ( Figure 2C ), consistent with the fact that this treatment regimen is strictly immune dependent (Sharma et al., 2015) . Adoptive transfer of WT dendritic-lineage CDPs had only modest effect, with tumors Please see also Figure S2 . showing some growth delay but no regression. However, transfer of WT monocytic cMoP cells fully restored anti-tumor activity in Batf3 -/-mice ( Figure 2C , green symbols).
Antitumor activity in Batf3 -/-mice could also be rescued by peripheral MDSCs. Using our in vitro differentiation model, subfractionation of the peripheral MDSC population showed that the specific precursor cells for the Ly6c + CD103
+ DCs were Ly6c + MDSCs that expressed both Gr-1 and CD11b ( Figure S3A ). This subset differentiated in vivo into Ly6c + CD103
+ DCs following intratumoral transfer ( Figure S2C ). We next asked which transcription factors might control the differentiation of Ly6c + CD103 + cells from their precursor cells. Exploratory analysis of selected genes associated with immunity, inflammation, and cellular senescence revealed that the Ly6c + CD103 + cells in treated tumors expressed several known targets of the transcription factor p53 (e.g., p21
Waf1 , p16 INK4a , and IRF5; data not shown). In the immune system, p53 has generally been associated with tolerance and immune suppression (Muñ oz-Fontela et al., 2016), but in certain settings p53 can also drive a pro-inflammatory program (Lowe et al., 2014; Slatter et al., 2015) . Prior to treatment, most of the immature Ly6c + cells expressed p53 ( Figure 3A ), but they did not show the phosphorylation at Ser15 that might suggest functional activation. (p53 has multiple phosphorylation sites, but in these studies we measured Ser15 as one hallmark of activation.) When mice were treated with CTX+VO-OHpic, a distinct population of cells acquired p53-Ser15 phosphorylation, and these corresponded closely to the Ly6c + CD103 + dual-positive cells ( Figure 3A , red circle).
Phosphorylation occurred rapidly, within 24 hr of treatment, and required both CTX and VO-OHpic ( Figures S3D and S3E ). To ask whether p53 was mechanistically required for differentiation of the Ly6c + cell population, even though they had other CD11c + cells ( Figure 3B ). The Trp53 -/-mice also had ample numbers of MDSCs, as previously reported (Guo et al., 2013) , but when the immature Ly6c + cells from Trp53 -/-mice were tested in vitro, they proved unable to differentiate into Ly6c + CD103 + cells ( Figure 3C ).
We therefore asked what downstream differentiation signals might be dependent on p53. Batf3 itself is not a known target of p53. However, the transcription factor IRF5 is a direct target of p53 (Mori et al., 2002) , and IRF5 is known to be a regulator of DC maturation (Lazzari and Jefferies, 2014) . Following CTX+VO-OHpic treatment, IRF5 expression corresponded closely with p53-Ser15 phosphorylation in CD11c + cells, and mice lacking p53 lost all IRF5 expression ( Figure 3D ). In vitro, siRNA silencing of IRF5 prevented upregulation of Batf3 in Ly6c + cells and markedly inhibited differentiation into the CD103 + phenotype ( Figure 3E ). Thus, taken together, these data suggested that p53 was required to induce IRF5 and that IRF5 was then required for activation of Batf3 and downstream differentiation of the Ly6c + CD103 + phenotype.
p53 Activation Is Triggered by the Myeloid Respiratory Burst Although p53 was clearly important, it was unclear how immunologic signals could activate the p53 pathway. The classic trigger would be DNA damage, mediated via the ATM kinase, but DNA damage seemed unlikely. However, ATM kinase can also be activated by reactive oxygen species (ROS) (Guo et al., 2010) , and ROS are produced by activated myeloid cells. In vitro, we found that Ly6c Figure 4A ). (In other studies, not shown, the source of IFN-g was shown to be the activated effector T cells.) This IFN-g-inducible respiratory burst was much greater than the lower amounts of ROS produced constitutively by the MDSCs (top histogram) (Thevenot et al., 2014) . In myeloid cells, one major source of inducible ROS is the gp91phox system (Cybb). When tumors were grown in Cybb -/-mice and treated with CTX+VO-OHpic, the ROS-deficient mice were unable to phosphorylate p53 in Ly6c + cells ( Figure 4B ). Consistent with this, downstream IRF5 was not induced, Batf3 was not upregulated, and the Ly6c + CD103 + cell population failed to differentiate ( Figure 4C ). Offering further support for the hypothesis that ATM kinase acted as the redox sensor for the respiratory burst, siRNA silencing of ATM substantially reduced p53 phosphorylation, decreased expression of IRF5, and blocked differentiation into Ly6c + CD103 + cells in vitro ( Figure 4D ).
In addition to ROS, we found that the Ly6c + CD103 + cells also expressed the nitric-oxide synthase NOS2 ( Figure S3F ). This finding linked the Ly6c
+ cell population to the inflammatory NOS2 + myeloid DCs (''Tip-DCs'') recently described in tumors during immunotherapy (Marigo et al., 2016) . Although the experimental systems are different, we suspect that the immunotherapy-induced Tip-DCs may reflect a similar pathway of immunogenic myeloid differentiation in inflamed tumors.
A Similar Inflammatory Pathway in Human Myeloid Cells Is Controlled by p53, IRF5, and Batf3
We next asked whether human cells possessed a p53-mediated pathway analogous to the mice. In vitro culture systems do not recapitulate the differentiation of authentic human DCs, but they were a useful model to test the specific mechanistic predictions arising from the mouse findings. Human peripheral-blood mononuclear cells were enriched for monocytic cells, then cultured in granulocyte macrophage colony stimulating factor (GM-CSF)+IL-6 (Koehn et al., 2015) . Many of the resulting cells expressed the myeloid marker CD33 + , but they lacked markers of maturation and activation such as CD83, CD141, and XCR1, and none expressed Batf3 ( Figure 5A ). When these cultures were treated with recombinant IFN-g (an activation stimulus analogous to the mouse co-cultures), many of the CD33 + cells rapidly upregulated CD83, CD141, and XCR1, as well as Batf3 (scatter plot, Figure 5A ).
Using this model, we asked whether the activation step was dependent on p53. siRNA against human p53 (TP53) effectively silenced p53 expression in transfected cells, and the loss of p53 entirely abrogated upregulation of the readout markers CD83, CD141, and XCR1 ( Figure 5B ). During activation, the CD33 + cells also upregulated IRF5 and Batf3, and both of these downstream transcription factors were lost when p53 was silenced. Mechanistically, siRNA silencing of either IRF5 or BATF3 prevented myeloid cell activation and expression of the readout markers ( Figures 5C and 5D ). Thus, within the limits of an in vitro model, the same p53/IRF5/Batf3 pathway found in the mice also appeared relevant to human myeloid cells.
Targeted Deletion of p53 Ablates the Ly6c
+ CD103 + Cell Population To test the in vivo biologic role of p53 in myeloid differentiation, we bred mice with a targeted deletion of p53 in myelomonocytic cells. For this we selected cre-recombinase driven by the Lyz2 promoter (Lyz2-cre), since this construct is expressed in many monocytic and macrophage cells, including Ly6c + monocytes (Gamrekelashvili et al., 2016) . To ask whether Lyz2-cre was expressed in the precursor cells that gave rise to Ly6c + CD103 + cells, fate-mapping studies were performed using Lyz2-cre crossed to Rosa26-STOP-flox-YFP reporter mice. This irreversibly marks any cells that have expressed Lyz2-cre during development. In untreated tumors ( Figure 6A , top), the few CD103 + DCs present at baseline were all negative for Ly6c (i.e., they were conventional cDCs), and these did not mark with Lyz2-cre-YFP. However, following treatment with CTX+VO-OHpic, the majority of CD103 + cells in tumors now became the dual-positive Ly6c + CD103 + cells, and most of these marked with YFP ( Figure 6A, bottom) . Analysis of immature MDSCs in TDLNs (Figure S4A) Figure S4B ). When these mice were treated with CTX+VO-OHpic, they showed a marked reduction in the Ly6c + CD103
+ population ( Figure 6B , red boxes).
This was selective for just the Ly6c + CD103 + DC subset: the overall number of CD11c + cells was comparable to WT controls ( Figure 6B , upper scatter plot, and S4C) and the number of ''conventional'' CD103 + cDCs (not expressing Ly6c) was also the same ( Figure S4D ). However, the specific Ly6c + CD103 + population was selectively lost in the absence of p53.
To test whether this was due to a cell-intrinsic defect in the differentiation of this population, we isolated p53-deficient precursor cells from spleens of tumor-bearing Lyz2-cre-Trp53 flox/flox mice and transferred them into WT mice with tumors. (For these studies we used peripheral MDSCs, because the Lyz2-cre promoter is not yet expressed in bone-marrow cMoPs [Gamrekelashvili et al., 2016] .) Following treatment with immunogenic chemotherapy, the Lyz2-cre-Trp53 flox/flox cells were able home to tumors, but they did not express p53 and they were unable to differentiate into Ly6c + CD103 + cells ( Figure 6C ). Within the same tumor, however, the endogenous (WT) cells differentiated normally into Ly6c + CD103 + cells. Thus, the p53-deficient precursors showed an inherent, cell-intrinsic defect in differentiation.
(The flow cytometry plots in Figure 6C further show that the Lyz2-cre promoter was quite efficient at deleting p53 in the Ly6c + cells that reached the tumor. In the inflammatory environment of the tumor, the penetrance of the Lyz2-cre promoter appeared to be high.) The loss of the Ly6c + CD103 + population had a profound impact on functional anti-tumor immunity ( Figure 6D ). Lyz2-creTrp53 flox/flox mice lost their ability to mount an anti-tumor response following CTX+VO-OHpic treatment, and tumors grew unchecked. This was specifically due to the absence of the Ly6c + CD103 + cell population, because adoptive transfer of p53-sufficient (WT) precursor MDSCs fully rescued anti-tumor activity ( Figure 6E ).
Lyz2-cre-Trp53
flox/flox mice were also unable to respond a potent regimen of T cell adoptive-transfer plus vaccination and dual checkpoint blockade ( Figure 6F) . Similarly, the Lyz2-cre-Trp53 flox/flox mice lost all response to a model of chemotherapy-induced immunogenic cell death (ICD) (Ghiringhelli et al., 2009) , comprising E.G7 tumors treated with oxaliplatin (Figure S4E) . ICD is known to be driven by inflammatory signals such as TLR4 and ATP receptors (Apetoh et al., 2007; Ghiringhelli et al., 2009) , and the Ly6c + CD103 + cells proved to be the main cells that expressed these receptors following oxaliplatin treatment (Figure S4F) . Thus, taken together, disrupting p53-dependent differentiation of the Ly6c + CD103 + monocytic cell population created a profound defect in multiple forms of anti-tumor immunity.
Therapeutic Augmentation of Ly6c + CD103 + Cells via a p53-Agonist Drug Given that the p53 pathway was so crucial, we asked whether increasing p53 would enhance the response to immunotherapy. In many cells, the expression of p53 is controlled by the ubiquitin-ligase MDM2. MDM2-inhibitor drugs are in clinical trials, intended to increase p53 expression in tumors (Khoo et al., 2014) . In our system, many host mononuclear cells in tumors expressed p53, with the highest expression found in CD11c + cells and myeloid cells ( Figure S5A ). Systemic treatment with the prototypical MDM2-inhibitor nutlin-3a (Vassilev et al., 2004) caused a 2-to 3-fold increase in mean fluorescence intensity of p53 staining in these high-expressing cells, specifically including Ly6c + myeloid cells.
To ask whether this would enhance immune responses, we employed a regimen of dual checkpoint blockade ( Figure 7A ). By itself, this had only modest effect against the highly resistant B16F10 model. However, the addition of nutlin-3a enhanced and prolonged the effect of immunotherapy. When examined 2 weeks after treatment, tumors that received checkpoint blockade alone were rapidly re-growing and had lost all Ly6c + CD103 + cells, whereas the addition of nutlin-3a maintained large numbers of Ly6c + CD103 + cells ( Figure 7A , dot plots) and the tumors were still small, inflamed, and regressing. Nutlin-3a had a similar enhancing effect on blockade of just the PD-1+PD-ligand pathway alone ( Figure S5B ). Nutlin-3a also showed an enhancing effect when added to CTX+VO-OHpic treatment ( Figure 7B ). All tumors initially shrank but in the absence of nutlin they progressively regrew once VO-OHpic treatment was stopped. Adding nutlin treatment markedly prolonged and sustained the anti-tumor effect. Likewise, adding nutlin-3a enhanced the response of E.G7 tumors to immunogenic oxaliplatin chemotherapy ( Figure 7C ) in a dose-dependent fashion ( Figures 7D and S5C) .
Finally, to ask whether the activity of nutlin was specifically due to an on-target effect on myeloid-lineage p53, we compared responses in Lyz2-cre-Trp53 flox/flox mice. In mice lacking myeloid p53, nutlin-3a lost all ability to enhance antitumor immunity ( Figure 7E ). (The same result was seen using the CTX+VO-OHpic regimen and also using checkpoint blockade therapy [data not shown].) Thus, the immuneenhancing activity of nutlin was a specific, on-target effect on myeloid-lineage p53.
The Immune-Activating Effect of p53 Is Context Specific for the Tumor Milieu This immune-enhancing effect of nutlin-3a seemed paradoxical, because in most settings p53 is considered immunosuppressive and tolerogenic (Muñ oz-Fontela et al., 2016) . We speculated that p53 actually plays two roles in the immune system: self-tolerance in normal tissues during physiologic cell death, but a pro-inflammatory role in specialized settings such as viral infection or immune surveillance of tumors. To test this, we used a model of OVA-expressing tumors implanted in RIP-mOVA mice, which constitutively express OVA in pancreatic islet cells. In these mice, OVA was thus both a self antigen and a tumor antigen, in different physical locations. When mice were treated with OVA-specific T cells plus CTX+VO-OHpic, the tumors shrank but the mice rapidly succumbed to lethal autoimmune diabetes ( Figure S7A ). Adding nutlin-3a to the regimen was able to selectively suppress OVA-specific T cell responses outside of the tumor (in normal pancreatic tissue), thus protecting the mice from lethal autoimmunity. However, inside the tumor milieu-where inflammation was driven by p53-induced Ly6c + CD103
+ cells-nutlin enhanced T cell responses against the same OVA antigen and markedly increased the anti-tumor response ( Figure S7A ). This same context-specific ability to activate tumor immunity while suppressing autoimmunity was seen when nutlin-3a was added to checkpoint blockade ( Figure S7B ) and with immunogenic oxaliplatin chemotherapy ( Figure S7C ). Thus, p53 showed a striking ability to enhance immune responses to a shared-self antigen in the context of the tumor, while actively suppressing lethal autoimmune responses elsewhere against the same antigen.
DISCUSSION
In the current study we have described a population of Ly6c Because their immature myeloid precursor cells are already pre-positioned in large numbers in the periphery and tumor, they can rapidly differentiate in response to inflammation, to cross-present the wave of antigens released from dying tumor cells. Hence, we propose that the pre-positioned myeloid Ly6c + CD103 + cells play a key role in initiating the self-amplifying ''cancer-immunity'' cycle following therapy (Chen and Mellman, 2013) , and this explains why they are so critical for effective anti-tumor immunity. Differentiation of the Ly6c + CD103 + population was controlled by the transcription factor p53. This finding identifies myeloid-lineage p53 as a previously unsuspected target for immunotherapy. Using nutlin-3a, a prototypical p53-agonist (MDM2-inhibitor) drug, we have shown anti-tumor immunity could be enhanced and prolonged by elevating p53 expression. A number of MDM2-inhibitor drugs are already in clinical trials for non-immunologic indications (Khoo et al., 2014) . Although these MDM2 inhibitors can be toxic at higher doses, we speculate that it may be possible to target the normal, physiologic regulation of p53 in host myeloid cells (in which p53 is already expressed and is highly inducible) at lower doses than required for resistant tumor cells.
As with any immunologic therapy, one major concern is always autoimmunity. In this regard p53 may represent a unique target, because of its inherently dichotomous role in the immune system. p53 can be immunosuppressive in certain contexts, yet can also be pro-inflammatory during infection or immune surveillance (Muñ oz-Fontela et al., 2016). In our models, targeting the p53 pathway had a remarkable ''location-dependent'' selective immune effect-able to promote activation of T cells in the context of the tumor (which was rich in Ly6c + MDSC precursor cells) yet actively suppressing responses against the same antigen when expressed as an autoantigen in normal tissues. This context-dependent selectivity could make p53 an attractive target for clinical immunotherapy.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: 
CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, David H. Munn (dmunn@augusta.edu).
EXPERIMENTAL MODEL AND SUBJECT DETAILS Animals
Animal studies were approved by the Institutional Animal Care and Use Committee, Augusta University. Mice were obtained from Jackson Laboratories or bred in-house, and maintained at 2-5 mice per cage in a Specific Pathogen-Free environment. For experiments, mice were used between 3-6 months of age. During the 2-3 week experimental period (tumor implantation and immunotherapy), mice were housed individually in an ABSL2 facility. Animals of both sexes were randomly assigned, and the results shown reflect pooled results with both genders.
Human materials
Human peripheral blood mononuclear (PBMC) samples for bead-enrichment were obtained from Memorial Blood Centers (Minneapolis, MN). Alternatively, myelomonocytic cells from normal volunteers were enriched by counter-flow centrifugal elutriation as previously described (Munn et al., 2004) , following informed consent under a protocol approved by the Institutional Review Board of the Medical College of Georgia, Augusta University. Samples were anonymized and genders are unknown, but both males and females are in both donor pools.
Cell lines
The B16F10 and E.G7 (EL4-OVA) cell lines were obtained directly from ATCC. Cells were cultured for 1 passage and re-frozen in multiple aliquots at the same early passage. Replicate aliquots (same passage) were used for one experiment and discarded. B16-OVA (B16F10 transfected with full-length chicken ovalbumin) clone MO4 (Falo et al., 1995) was the gift of A. Houghton, Memorial Sloan Kettering. B16F10 cells expressing EGFP protein (B16-GFP cells) were derived using lentiviral transfection. Cell lines were not routinely authenticated by us, but melanoma lines were monitored and photographed for melanoma production in vivo, and lines expressing GFP or OVA were routinely screened for production of the transgene (by flow cytometry or stimulation of OT-I T cells, respectively).
METHODS DETAILS Reagents
Human hgp100 25-33 (KVPRNQDWL) peptide and OVA SIINFEKL peptide were synthesized by Southern Biotechnology from the published sequences (Hogquist et al., 1994; Overwijk et al., 2003) . VO-OHpic was from Biovision (#1801-5). Whole OVA protein (#A-5503) and N-acetyl-L-cysteine (#A-7250) were from Sigma. Nutlin-3a (#18585) was from Cayman Chemical. Indoximod (1-methyl-D-tryptophan, clinical grade) was obtained from NewLink Genetics, or from Sigma-Aldrich (#452483) and was dissolved as described (Sharma et al., 2013) . Flt3L neutralizing antibody was from R&D Systems (#AF427) and was used at 10 ug/ml.
Mouse strains
The following were obtained from Jackson Laboratories and bred in our colony:
d OT-I mice (CD8 + , recognizing the SIINFEKL peptide of ovalbumin on H2K (Kurts et al., 1996) 
The Tg(Grm1)Epv mouse strain (Pollock et al., 2003) was the generous gift of S. Chen, Rutgers University, and was monitored weekly for development of autochthonous melanoma.
Pten À/À Foxp3-cre mice have been described previously (Sharma et al., 2015) .
Lyz2-cre-Trp53
flox/flox mice were derived in Dr. Yan Cui's laboratory. Lyz2-cre mice (B6.129P2-Lyz2 tm1(cre)Ifo /J, strain 004781, Jax), which bear a nuclear-localizing Cre-recombinase replacing one copy of the Lyz2 gene (Clausen et al., 1999) 
Foxp3-cre and Lyz2-cre-Trp53
flox/flox mice were inbred on the B6 background, so in validation studies we compared controls using the Creexpressing parental strain, versus littermates negative for Cre, versus wild-type C57BL/6 mice. All three controls gave comparable results for tumor growth, anti-tumor response and flow cytometry assays. Therefore, to minimize wastage of mice, WT B6 mice were used as controls for these strains, similar to the other mutant strains.
Mouse myeloid-cell maturation cultures Ly6c + immature myeloid were isolated from either tumors, TDLNs or spleens of tumor-bearing mice. In the case of TDLN and spleen, a very pure population of precursor cells could be sorted as Ly6c + CD11b -CD11b + Gr-1 + . However, when isolating cells from disaggregated tumors, we found that many of the Ly6c + precursor cells down-modulated their CD11b expression in the tumor. Therefore, to isolate precursor cells from tumors, we sorted a bulk population of Ly6c + CD11c -cells. This contained all of the precursor cells and made no assumptions about CD11b expression; and high purity was not required for these studies. (In many sorts, we also routinely used B220 staining to exclude pDCs or activated B cells, some of which might in theory express Ly6c. In practice, however, we did not see any B220
+ cells in the Ly6c + gate.) Rapid isolation of cells was important for viability, so cells were disaggregated by passing once through a 40 um mesh, then stained briefly on ice and flow-sorted into ice-cold medium using low-shear fluidics and a large nozzle (Mo-Flo cell sorter). Maturation cocultures were performed in V-bottom wells (Nunc 249952 V96), using RPMI-1640 medium with 10% fetal bovine serum, but no added cytokines.
Sorted Ly6c + myeloid cells were added to co-cultures as previously described (Sharma et al., 2013) . As an inflammatory stimulus for differentiation, CD8 + effector cells (5 3 10 4 ) were flow-sorted from spleens of either OT-I or pmel-1 mice (both performed equivalently), and added to co-cultures along with 100 nM cognate peptide (SIINFEKL or hgp100 ) to maintain T cell viability. All T cells and feeder layer were made CD45.1 + or Thy1.1 + , so that they could be excluded from analysis after culture.
To ensure that activation was not suppressed by either IDO from the myeloid cells, or PTEN expression by the Treg cells, all cultures received inhibitors of IDO (1-methyl-D-tryptophan (indoximod), clinical grade, 200 uM) and PTEN (VO-OHpic, 1 uM). After 3 days, co-cultures were harvested and stained for maturation of the original myeloid population, gated on the congenic markers to exclude other cells.
Human myeloid-cell cultures
Human PBMC samples were obtained from Memorial Blood Centers (Minneapolis, MN) and isolated by centrifugation over FicollPaque PLUS (GE Healthcare), followed by enrichment for myeloid cells using CD33 + micro-beads (Miltenyi MACs). Alternatively, myelomonocytic cells were enriched by counter-flow elutriation as previously described (Munn et al., 2004) . Both starting preparations gave similar results. Immature myeloid cells were then generated by culture for 7 days as previously described (Koehn et al., 2015) , using RPMI-1640 medium with 10% FBS, 1% Pen/Strep, 1% GlutaMax plus recombinant human GM-CSF (10ng/ml, R&D Systems) and IL-6 (10ng/ml, R&D Systems). Culture growth media was refreshed on days 3 and 6. On day 8, recombinant human IFNg (30ng/ml, R&D Systems) was added to induce maturation (or vehicle control). After 48 hr, cultures were harvested and stained.
siRNA silencing
To maximize viability and function, very gentle transfection conditions were chosen, with a goal of achieving $50%-60% transfection. Transfected cells were then identified based on uptake of FITC-conjugated tracer oligos (#sc-36869), and these cells were gated for analysis. Using our conditions, mouse Ly6c + myeloid cells took up siRNA in 58 ± 9% of the original population at the end of culture, and human transfection efficiency was similar.
siRNA pools were obtained from Santa Cruz Biotechnology as follows: mouse: Batf3 (#sc-153654), Irf5 (#sc-72045) and Atm (#sc-29762); human: IRF5 (#sc-72044), TP53 (#sc-29435) and BATF3 (#sc-88553); each with associated scrambled control siRNA.
Transfection of mouse cells were performed using the manufacturer's siRNA Reagent Kit (#sc-45064). Briefly, Ly6c + CD11c -myeloid cells were sorted from TDLNs, and combined with other cells as for the maturation co-cultures described above. Prior to plating, the mixed cells were suspended in Transfection Medium and incubated with specific siRNA or control scrambled siRNA, diluted in Transfection Reagent. After 6 hr at 37 C, 2 3 growth medium was added (RPMI-1640 with 20% FBS and double the supplements), and cells cultured overnight. (The siRNA was not removed during culture). After 24 hr, most of the transfection medium was gently aspirated and replaced by 1 3 culture medium, and cultures continued for an additional 60 hr.
Human cells were transfected similarly. Myeloid cells were cultured, and siRNA was added on day 8 (at the time of IFNg addition). After 6 hr at 37 C, most of the transfection medium was gently aspirated and replaced by culture medium with fresh cytokines, and cultures continued for an additional 2 days.
Antigen-presentation co-cultures and rescue of T cell anergy Antigen-presentation. For ex-vivo antigen-presentation assays, APCs were harvested from tumors (rather than TDLNs) so that they would have been directly exposed to tumor antigen. Mice bearing B16-OVA, B16F10 or E.G7 tumors were treated with PTEN-inhibitor immunotherapy (VO-OHpic day 9-14 + CTX day 10). Tumors were harvested on day 14 and disaggregated with collagenase, DNase and hyaluronidase as described (Sharma et al., 2015 the feeder layer and Treg cells used in the maturation cultures were not necessary and were omitted.) Co-cultures were set up in triplicate and proliferation measured after 3 days by 3 H-thymidine incorporation. Some wells received recombinant IL-12 (R&D systems, #419-ML/CF, 40 ng/ml) or IL-12 neutralizing antibody (anti-IL-12p40, clone C17.8, BioXcell, 1 ug/ml).
Antibodies and flow cytometry staining
The conjugated antibodies used for flow cytometry are listed in the Key Resources Table. For staining of mouse lymph nodes, cells were prepared by rapidly passing the whole node through a 40 um mesh, then stained using short incubation times (10 min on ice), as described (Sharma et al., 2013) . Tumors were disaggregated by treating for 1 hr with collagenase, DNase and hyaluronidase in RPMI 1640 medium, as described (Sharma et al., 2015) .
Mouse CD11c was detected with clone HL3, to minimize cross-reactivity with macrophages. Since the available antibodies for human XCR1 have not been validated for in vitro diagnostic use, two different clones were used for confirmation (clone RTK2758 from BioLegend, and clone 1097A from R&D systems); both gave identical staining results, so the marker appeared informative.
For intracellular IL-12 detection we used antibody against the p40 subunit (clone C17.8) (Ruffell et al., 2014) . There was no evidence of a role for IL-23 in our system, and results were confirmed using exogenous recombinant IL-12.
All intracellular antigens except for phospho-p53 were detected using fixation-permeabilization reagent and matching perm-wash buffer from eBioscience (Cat. #00-5523), with blocking using 5% normal donkey serum, then acquired immediately after staining. IL-12 and IFNg were measured after 4 hr activation with PMA+ionomycin in the presence of brefeldin A as previously described (Sharma et al., 2013) .
Reactive oxygen species (ROS) were measured using the redox-responsive dye 2 0 ,7 0 -dichlorofluorescein diacetate (DCFDA) as described (Thevenot et al., 2014) .
Antibody against the N terminus of mouse p53 (clone 1C12) was from Cell Signaling Technology. Antibody against the C terminus of p53 (clone PAb122) was from Novus Biologicals. For both antibodies, staining was performed following permeabilization with eBioscience fix-and-perm. Anti-phospho-p53(Ser15) (clone D4S1H) was from Cell Signaling Technology. For phospho-specific staining, cells were washed in PBS, fixed with 2% paraformaldehyde for 10 min at 37 C, pre-chilled for 1 min, then permeabilized by slow addition of ice-cold methanol to a final concentration of 90%. Cells were then incubated on ice for 30 min, washed with 1% FCS in PBS, blocked with the same solution for 10 min at room temperature, then for 1 h at room temperature and washed. Cells were acquired immediately after staining.
Validation of p53 staining. It was critical that we be able to detect p53 in individual cells by flow cytometry (rather than by bulk western blot) because many cells in the tumor expressed p53, but only the specific Ly6c + CD103 + monocytic cell subset was of interest. The antibodies for flow cytometry were specific, as shown in Figures S3B and S3C . However, clone 1C12 and the phospho-specific clone D4S1H both bound near the same residues, and showed stearic hindrance. Therefore, we used clone Pab122 for all dual-staining. To increase rigor, all conclusions from flow cytometry were confirmed by one or more complementary strategies (Trp53 -/-mice, targeted Lyz2-cre-Trp53 flox/flox mice, pifithrin inhibitor, or siRNA silencing of downstream target genes).
In vivo tumor studies Tumor implantation was performed as described (Sharma et al., 2013) , using 1 3 10 5 cells for B16F10 and 1 3 10 6 cells for other cell lines (large inocula were used to ensure rapid tumor engraftment and immune suppression). Tumors were implanted bilaterally in each mouse as a control for reproducible implantation technique; replicate tumor diameters in a single mouse were typically within ± 15%. Tumor volume was calculated from orthogonal diameters using the formula V = L 3 W 2 3 p/6. Mice received approved euthanasia when tumors reached a size of 300 mm 2 (product of orthogonal diameters); death was never used a planned endpoint in any study.
CTX+VO-OHpic, nutlin-3a, oxaliplatin and immunotherapy regimens For chemotherapy, cyclophosphamide was given at 150 mg/kg i.p 3 1 dose. Oxaliplatin was given at 5 mg/kg i.p 3 1 dose. The vanadate compound VO-OHpic (Mak et al., 2010) inhibits PTEN activity, and we used this drug to destabilize PTEN + Tregs during chemotherapy. Like all of the available PTEN-inhibitors, VO-OHpic can also affect other phosphatases. However, it is an effective inhibitor of PTEN in vivo, and we have shown that when VO-OHpic is combined with chemotherapy, it causes rapid and essentially complete destabilization of PTEN + Tregs in tumors (Sharma et al., 2015) . VO-OHpic is not selective just for Tregs, but the Tregs in tumors appeared particularly dependent on PTEN in order to maintain their suppressive phenotype. In contrast, effector T cells and APCs expressed little PTEN during activation, and showed little effect of PTEN-inhibitor (Sharma et al., 2015) . Thus, with these due caveats, VO-OHpic was an effective means of functionally destabilizing PTEN + Tregs during chemotherapy. VO-OHpic was given at 10 mg/kg/day i.p., in 10% DMSO in PBS.
Nutlin-3a was dissolved at 2 mg/ml in 10% DMSO in buffered saline, and administered daily at 10 mg/kg/day i.p., or as indicated The 10 mg/kg/day dose was at the lower end of the published parenteral dosing range described for mice (Zhang et al., 2011) .
For checkpoint blockade, mice received anti-CTLA-4 (clone 9D9, BioXcell) and/or a cocktail of antibodies against the PD-1 pathway comprising: anti-PD-L2, clone TY25 (Yamazaki et al., 2002) ; anti-PD-1, clone J43 (Agata et al., 1996) ; and anti-PD-L1, clone MIH7 (Tsushima et al., 2003) , generous gift of Dr. Miyuki Azuma. A combined cocktail was used in order to block the PD-1 pathway as completely as possible, and thus minimize any peculiarities of a single blocking antibody.
Ly6c
+ MDSC adoptive transfer (intra-tumoral and systemic)
For all adoptive-transfer studies, cells were stained briefly on ice then sorted into ice-cold medium using low-shear fluidics and a large-aperture nozzle (Mo-Flo cell sorter). For intra-tumoral injection of MDSCs, we modified the approach of Zitvogel and colleagues (Ma et al., 2013) . Donor mice (CD45.1 congenic) were implanted with B16F10 tumors, then on day 14 tumors were harvested, disaggregated as described for flow-cytometry staining, and Ly6c + MDSCs sorted as Ly6c + CD11c -cells (with B220 -used to exclude any B cells and pDCs that might express Ly6c). In parallel, the recipient mice were implanted with B16F10 tumors (5 days delayed), then the sorted Ly6c + CD11c -cells injected into new recipient tumors on day 9 of tumor growth (1 3 10 6 sorted cells in 50 ul PBS). Recipient mice were then treated with CTX+VO-OHpic, and tumors harvested 4 days after transfer. For systemic adoptive-transfer, immature myeloid cells (Ly6c + CD11c -CD11b + Gr-1 + ) were sorted from the MDSC pool in spleens of tumor-bearing mice. To obtain the maximum yield of MDSCs, donor mice were usually implanted with EL4 tumors for 21 days. It was immaterial which tumor elicited the precursors in donor mice, since these were not antigen-specific, and EL4 tumors elicited large numbers of MDSCs.
To isolate bone-marrow precursors (cMoPs and CDPs), tibias of normal C57BL/6 mice (without tumors) were flushed, filtered through 40 um mesh, and sorted for the markers described in the text.
Vaccine and T cell adoptive transfer
For tumor vaccines, human gp100 25-33 was synthesized from the published sequence (Overwijk et al., 2003) . CpG-1826 (phosphorothioate oligo 5 0 -TCCATGACGTTCCTGAGCTT-3 0 ) was synthesized from the published sequence (Chu et al., 1997) by Tri-link Biotechnologies. Vaccines were prepared with 25 ug peptide and 50 ug CpG-1826 in incomplete Freund's adjuvant (IFA, Sigma F-5506) and administered in the hind-limb footpad. For adoptive transfers, OT-I or pmel-1 spleen cells were enriched by negative selection using magnetic beads (mouse CD8 isolation kit II, #130-095-236, Miltenyi Biotech), or by MoFlo cell sorting using a large-aperture nozzle. Staining for sorting was performed on ice with short incubation times to keep the cells viable but un-activated. Mice received 2 3 10 6 enriched CD8 + cells via tail-vein.
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical analysis was performed using GraphPad Prism 7.01 software. For two groups, means were compared by t test. For multiple treatment groups, analysis was by ANOVA with Tukey's correction for multiple comparisons. Tumor-growth studies were treated as end-point analyses, and groups compared by t test or ANOVA at the end of the measurement period. For all scatter-plots, the data shown were pooled from at least 3 independent experiments (the number of independent experiments are indicated in the legends). Error bars in figures show standard deviation. A P value of < 0.05 was considered significant.
